Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > REGULATORY
REGULATORY
- 1st Committee on Drugs to Discuss Approval for JT’s Hyperphosphatemia Treatment on October 28
October 18, 2013
- 60% of Products/Indications in 1st Round of Development Requests Approved as of June: MHLW
October 18, 2013
- CSIMC Pricing Subcommittee OKs Indicator to Gauge Reasonableness of Premium’s Perpetuation
October 17, 2013
- CSIMC to Study Introduction of Medical Fee for DPC Hospitals with High Generic Drug Use Rates in Fee-for-Service System
October 17, 2013
- PMDA to Kick Off Pilot Program for Electronic Filings of NDA Data in October
October 16, 2013
- Japan “Hopes to Find Common Ground” in Upcoming TPP Talks on Intellectual Properties: Minister Amari
October 16, 2013
- Generic-Name Prescribing Promoted Use of Generic Drugs in FY2012: CSIMC Committee
October 11, 2013
- CSIMC Pricing Subcommittee to Explore “Responses” to Diovan Uproar
October 10, 2013
- Expert Group Calls for Handling of Switch OTC Drugs as Careful as Ethical Drugs in Early Stage after Switching
October 10, 2013
- Working Group Finalizes Recommendation on Rules for Online Sales of OTC Drugs
October 10, 2013
- MHLW Formally Compiles Interim Report of Expert Panel on Diovan Scandal
October 10, 2013
- Applications Based on Information in Public Domain Appropriate for 4 Drugs Including Vancomycin: Council on Unapproved Drugs
October 9, 2013
- Nonpartisan Lawmaker Group to Hold Study Session on Diovan Scandal
October 8, 2013
- Council on Regulatory Reform to Begin Holding Open Public Discussions Later This Year
October 8, 2013
- Addition of TACE Use for Farmorubicin to Be Reported to PAFSC Second Committee
October 7, 2013
- NIBIO to Strengthen Academia’s Drug Discovery Support Initiatives in Order to Evaluate 400 Research Themes by FY2015
October 4, 2013
- PMDA Considers Offering Development Strategy Consultations to Drug Makers: Office Director
October 3, 2013
- Industrial Competitiveness Council Finalizes Enforcement Policy for New Growth Strategy; Recommends Name for Japanese Version of NIH
October 3, 2013
- PMDA Branch in Kansai Region Officially Opens
October 2, 2013
- Interim Report of Diovan Panel Fails to Lay Bare Who Altered Data, for What Purpose
October 1, 2013
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…